Immatics

IMTX

Market cap $707M

Overview Fund Activity

5.82 USD

-0.10

1.69%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

6.17

+0.35

6.01%

1 day

-1.69%

5 days

-6.88%

1 month

-9.35%

3 months

-5.21%

6 months

27.91%

Year to date

-21.56%

1 year

-53.29%

5 years

-36.46%

10 years

-39.37%

About: Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Employees: 423

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,683% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $64K

41% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 17

22% more capital invested

Capital invested by funds: $412M [Q1] → $501M (+$88.8M) [Q2]

0.06% more ownership

Funds ownership: 76.54% [Q1] → 76.6% (+0.06%) [Q2]

9% less funds holding

Funds holding: 76 [Q1] → 69 (-7) [Q2]

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Financial journalist opinion

Zacks Investment Research

New Strong Sell Stocks for August 15th

IMTX, ERJ and BFIN have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2025.

New Strong Sell Stocks for August 15th

Zacks Investment Research

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Immatics (IMTX) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.18 per share a year ago.

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Immatics Announces Second Quarter 2025 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, August 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today provided a business update and reported financial results for the quarter ended June 30, 2025.

Immatics Announces Second Quarter 2025 Financial Results and Business Update

Zacks Investment Research

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?

The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Stafford , Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor.

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

Immatics Announces First Quarter 2025 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2025.

Immatics Announces First Quarter 2025 Financial Results and Business Update

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois.

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Immatics N.V.: Trading Below Cash, But Not Without Reason

Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert. Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty.

Immatics N.V.: Trading Below Cash, But Not Without Reason

Immatics Announces Full Year 2024 Financial Results and Business Update

Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.

Immatics Announces Full Year 2024 Financial Results and Business Update

Zacks Investment Research

New Strong Buy Stocks for February 12th

BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025.

New Strong Buy Stocks for February 12th

See News Rankings

Charts implemented using Lightweight Charts™